We are live on ! Find out more
YARW

Yarrow Bioscience, Inc. Common Stock

38 hedge funds and large institutions have $1.1M invested in Yarrow Bioscience, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

3% more funds holding

Funds holding: 3738 (+1)

0% less ownership

Funds ownership: 0.02%0.01% (-0%)

40% less capital invested

Capital invested by funds: $1.84M → $1.1M (-$738K)

73% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 11

Holders
38
Holders Change
+1
Holders Change %
+2.7%
% of All Funds
0.61%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
3
Reduced
11
Closed
3
Calls
Puts
Net Calls
Net Calls Change

YARW Hedge Fund Activity: Q4 2022 in Review

38 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q4 2022, worth a combined $1.1M — down 40% from $1.84M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new YARW positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 11 trimmed.

The largest buyer was Millennium Management, adding an estimated $64.1K. The largest seller was DSC Advisors, cutting an estimated $244K.

  • 38 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q4 2022, up from 37 in Q3 2022.
  • Funds reported $1.1M of Yarrow Bioscience, Inc. Common Stock stock for Q4 2022, down 40% quarter-over-quarter.
  • 4 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q4 2022 and 3 closed out, a net change of +1 holder.
  • The largest Yarrow Bioscience, Inc. Common Stock buyer in Q4 2022 was Millennium Management, an estimated $64.1K added.
  • The largest Yarrow Bioscience, Inc. Common Stock seller in Q4 2022 was DSC Advisors, an estimated $244K sold.

Based on aggregated 13F filings for Q4 2022.